Non-specific interstitial pneumonia

Summary

Non-specific interstitial pneumonia (MONDO:0019622) is a disease and 7 clinical trials. Top therapeutic interventions include bosentan. A subtype of idiopathic interstitial pneumonia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	non-specific interstitial pneumonia
Mondo ID	MONDO:0019622
Orphanet	91364
DOID	DOID:2801
NCIT	C35717
SNOMED CT	129452008
UMLS	C1290344
MedGen	220936
GARD	0019167
Is cancer (heuristic)	no

Also known as: non-specific idiopathic interstitial pneumonia · nonspecific interstitial pneumonia · NSIP

Disease family

This is a subtype of idiopathic interstitial pneumonia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › respiratory tract infectious disorder › pneumonia › idiopathic interstitial pneumonia › non-specific interstitial pneumonia

Related subtypes (9): lymphoid interstitial pneumonia, desquamative interstitial pneumonia, cryptogenic organizing pneumonia, combined pulmonary fibrosis-emphysema syndrome, acute interstitial pneumonia, respiratory bronchiolitis-interstitial lung disease syndrome, idiopathic pleuroparenchymal fibroelastosis, follicular bronchiolits, idiopathic pulmonary fibrosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	6
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00637065	PHASE4	UNKNOWN	Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study
NCT03800017	Not specified	RECRUITING	Skeletal Muscle Function in Interstitial Lung Disease
NCT05007340	Not specified	RECRUITING	ILD-SARDs Registry and Biorepository
NCT06644144	Not specified	RECRUITING	P4O2 ILD Extension
NCT02596841	Not specified	COMPLETED	Lung Diffusing Capacity for Nitric Oxide as a Marker of Fibrotic Changes in Idiopathic Interstitial Pneumonias
NCT02827734	Not specified	UNKNOWN	Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)
NCT03836417	Not specified	COMPLETED	Molecular Diagnosis of Idiopathic Interstitial Pneumonias: a Prospective Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BOSENTAN	4	1